117 related articles for article (PubMed ID: 32231185)
1. Structural changes of serum albumin in response to oxidative stress caused by Walker-256 carcinosarcoma growth.
Sarnatskaya VV; Yushko LA; Prokopenko IV; Hudenko NV; Maslenny VN; Paziuk LM; Bubnovskaya LN; Nikolaev VG
Exp Oncol; 2020 Mar; 42(1):40-45. PubMed ID: 32231185
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of biochemical and morphological parameters in rats with Walker 256 and Walker 256/DOX carcinosarcoma.
Yushko LA; Sarnatskaya VV; Sakhno LA; Hudenko NV; Paziuk LM; Maslenny VN; Melnyk VO; Nikolaev VG
Exp Oncol; 2021 Mar; 43(1):21-25. PubMed ID: 33785723
[TBL] [Abstract][Full Text] [Related]
3. Morphological features of doxorubicin-resistant Walker 256 carcinosarcoma and response of mast cells.
Boroday NV; Chekhun VF
Exp Oncol; 2018 Mar; 40(1):42-47. PubMed ID: 29600974
[TBL] [Abstract][Full Text] [Related]
4. Remodulating effect of doxorubicin on the state of iron-containing proteins, and redox characteristics of tumor with allowance for its sensitivity to cytostatic agents.
Chekhun VF; Lozovska YV; Burlaka AP; Ganusevich LI; Shvets YV; Lukyanova NY; Todor IM; Tregubova NA; Naleskina LA
Ukr Biochem J; 2016; 88(1):99-108. PubMed ID: 29227592
[TBL] [Abstract][Full Text] [Related]
5. Effect of alpha tocopherol acetate in Walker 256/B cells-induced oxidative damage in a rat model of breast cancer skeletal metastases.
Badraoui R; Blouin S; Moreau MF; Gallois Y; Rebai T; Sahnoun Z; Baslé M; Chappard D
Chem Biol Interact; 2009 Dec; 182(2-3):98-105. PubMed ID: 19781538
[TBL] [Abstract][Full Text] [Related]
6. METALLOPROTEINS DURING DEVELOPMENT OF WALKER-256 CARCINOSARCOMA RESISTANT PHENOTYPE.
Chekhun VF; Lozovska YV; Burlaka AP; Ganusevich II; Shvets YV; Lukianova NY; Todor IM; Demash DV; Pavlova AA; Naleskina LA
Ukr Biochem J; 2015; 87(2):103-12. PubMed ID: 26255344
[TBL] [Abstract][Full Text] [Related]
7. Quantification and morphologic demonstration of reactive oxygen species produced by Walker 256 tumor cells in vitro and during metastasis in vivo.
Soares FA; Shaughnessy SG; MacLarkey WR; Orr FW
Lab Invest; 1994 Oct; 71(4):480-9. PubMed ID: 7967504
[TBL] [Abstract][Full Text] [Related]
8. Metabolic changes during development of Walker-256 carcinosarcoma resistance to doxorubicin.
Todor IN; Lukyanova NY; Shvets YV; Lozovska YV; Chekhun VF
Exp Oncol; 2015 Mar; 37(1):19-22. PubMed ID: 25804226
[TBL] [Abstract][Full Text] [Related]
9. Walker carcinosarcoma cells damage endothelial cells by the generation of reactive oxygen species.
Shaughnessy SG; Buchanan MR; Turple S; Richardson M; Orr FW
Am J Pathol; 1989 Apr; 134(4):787-96. PubMed ID: 2705506
[TBL] [Abstract][Full Text] [Related]
10. Proinflammatory effects of photoactivated methylene blue on rat model of Walker 256 carcinosarcoma.
Petrellis MC; Frigo L; Ribeiro W; Leal-Junior EC; Oliveira FR; Maria DA; Lopes-Martins RÁ
Exp Oncol; 2019 Jun; 41(2):112-122. PubMed ID: 31262159
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium complex exerts antineoplastic effects that are mediated by oxidative stress without inducing toxicity in Walker-256 tumor-bearing rats.
Alves de Souza CE; Alves de Souza HM; Stipp MC; Corso CR; Galindo CM; Cardoso CR; Dittrich RL; de Souza Ramos EA; Klassen G; Carlos RM; Correia Cadena SMS; Acco A
Free Radic Biol Med; 2017 Sep; 110():228-239. PubMed ID: 28629835
[TBL] [Abstract][Full Text] [Related]
12. Effects induced by a 50 Hz electromagnetic field and doxorubicin on Walker-256 carcinosarcoma growth and hepatic redox state in rats.
Orel VE; Krotevych M; Dasyukevich O; Rykhalskyi O; Syvak L; Tsvir H; Tsvir D; Garmanchuk L; Orel VВ; Sheina I; Rybka V; Shults NV; Suzuki YJ; Gychka SG
Electromagn Biol Med; 2021 Oct; 40(4):475-487. PubMed ID: 34392747
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis-like changes in Walker carcinoma 256-bearing rats, not accompanied with hypercalcemia or parathyroid hormone-related protein production.
Waki Y; Miyamoto K; Kasugai S; Ohya K
Jpn J Cancer Res; 1995 May; 86(5):470-6. PubMed ID: 7540609
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone.
Kostenuik PJ; Singh G; Suyama KL; Orr FW
Clin Exp Metastasis; 1992 Nov; 10(6):411-8. PubMed ID: 1451351
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma.
Guaitani A; Corada M; Lucas C; Lemoine A; Garattini S; Bartosek I
Cancer Chemother Pharmacol; 1991; 28(4):293-7. PubMed ID: 1879046
[TBL] [Abstract][Full Text] [Related]
16. Total proteolytic activity and content of the main proteinase inhibitors in blood plasma of rats bearing doxorubicin-sensitive and doxorubicin-resistant Guerin carcinoma.
Chekhun VF; Kovtonyuk OV; Todor IN; Kulik GI; Tryndiak VP
Exp Oncol; 2004 Sep; 26(3):232-5. PubMed ID: 15494693
[TBL] [Abstract][Full Text] [Related]
17. Vitamin C mitigates oxidative/nitrosative stress and inflammation in doxorubicin-induced cardiomyopathy.
Akolkar G; da Silva Dias D; Ayyappan P; Bagchi AK; Jassal DS; Salemi VMC; Irigoyen MC; De Angelis K; Singal PK
Am J Physiol Heart Circ Physiol; 2017 Oct; 313(4):H795-H809. PubMed ID: 28710069
[TBL] [Abstract][Full Text] [Related]
18. Postmenopause-like bone loss by mammary carcinoma Walker256/S which secretes luteinizing hormone-releasing hormone.
Waki Y; Miyamoto K; Yamamoto S; Saitoh Y; Kasugai S; Ohya K
Jpn J Pharmacol; 1999 Jun; 80(2):119-25. PubMed ID: 10440530
[TBL] [Abstract][Full Text] [Related]
19. Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery.
Zou Y; Yamagishi M; Horikoshi I; Ueno M; Gu X; Perez-Soler R
Cancer Res; 1993 Jul; 53(13):3046-51. PubMed ID: 8319211
[TBL] [Abstract][Full Text] [Related]
20. Rutin protects against neuronal damage in vitro and ameliorates doxorubicin-induced memory deficits in vivo in Wistar rats.
Ramalingayya GV; Cheruku SP; Nayak PG; Kishore A; Shenoy R; Rao CM; Krishnadas N
Drug Des Devel Ther; 2017; 11():1011-1026. PubMed ID: 28408800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
